Laboratorios Farmaceuticos Rovi, S.A. ROVI.MC
Composite 61/100; the shares have moved about 31% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Momentum ranks 30/100 — a moderate mark against it.
Balance-sheet strength ranks 85/100 — a strong point in its favour. Quality ranks 73/100 — a moderate point in its favour. Valuation ranks 64/100 — a moderate point in its favour.
Momentum ranks 30/100 — a moderate mark against it. Growth ranks 40/100 — a slight mark against it.
What the company does Laboratorios Farmaceuticos Rovi, S.A. (ROVI.MC) manufactures and markets prescription pharmaceuticals, hospital products, catheter care, and contract-manufacturing services across Spain, the EU, and OECD markets. Its portfolio includes specialty generics, low-molecular-weight heparins (e.g., Okedi, Rolcya), and early-stage pipeline assets like Letrozole SIE and Risperidone QUAR.
Key financials ROVI reports strong profitability with ROE 28.6%, ROA 9.4%, and ROCE 27.3%. Revenue grew 20.0% while EPS surged 246.7%. Margins are robust: gross 64.7%, operating 9.4%, and net 24.0%. The balance sheet is conservative with debt/equity 0.15 and net debt/EBITDA -0.12.
Stock health Quality and growth metrics are exceptional (Quality 71.8, Growth 88.4), but momentum is weak (Momentum 31.2). The stock is down -24.08% over 3 months and -16.16% over 6 months, though up 13.42% over 12 months. RSI(14) at 64.90 suggests mild overbought conditions.
Price vs fair value The stock trades at a **discount** of 34.70% to our fair-value estimate and a **discount** of 25.49% to the analyst 12-month target. - High forward P/E of 36.63 vs trailing P/E 16.40 signals growth expectations are priced in (Valuation). - PEG of 1.26 and EV/EBITDA of 11.11 remain above peer medians despite strong fundamentals (Valuation). - Analyst count of 9.0 supports valuation discipline (Analyst 12-month target). - Weak short-term momentum (-24.08% 3m) may be tempering near-term sentiment (Momentum).
Looking forward Rovi’s pipeline and contract manufacturing growth support long-term value, but high valuation multiples and soft momentum cap upside. Execution on Okedi, Rolcya, and pipeline assets will be key to justifying current expectations.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-05, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.